Table 1.

Patient characteristics of the overall cohort and the prognostic score-matched cohort

CharacteristicOverall Cohort, n=12,564aPrognostic Score-Matched Cohortb
Control Strata, N Strata=2501cSevelamer-Treated Patients, N Patients=2501
Demographics
 Age, yr64±1464±1061±14
 Men, %605958
 Time on dialysis, mo24 (7–64)44 (30–71)25 (6–65)
 BMI, kg/m225.7±6.225.5±3.526.1±6.3
 Single-pool Kt/V1.45±0.321.46±0.151.43±0.32
Comorbidities, %
 Coronary heart disease454344
 Cancer141312
 Other cardiovascular disease323031
 Cerebrovascular disease161614
 Congest heart failure333134
 Diabetes454345
 GI bleeding544
 Hypertension848485
 Lung disease131112
 Neurologic disease11109
 Psychiatric disorder141313
 Peripheral vascular disease272424
 Recurrent cellulitis/gangrene978
Laboratory tests
 Albumin, g/dl3.7±0.53.8±0.33.8±0.4
 Hemoglobin, g/dl11.3±1.511.4±0.911.3±1.4
 BUN (predialysis), mg/dl61±1861±963±18
 Creatinine, mg/dl8.4±3.08.8±2.29.3±2.9
 Calcium, mg/dl8.9±0.99.0±0.39.2±0.9
 Phosphorus, mg/dl5.2±1.65.1±0.85.8±1.7
 Intact PTH, pg/ml193 (98–336)243 (172–324)217 (105–380)
 Total cholesterol, mg/dl160±42159±19159±41
Medication, %
 ESA878888
 Active vitamin D derivativesd
  Oral333734
  IV242224
 Calcium carbonatee696360
 Lanthanum carbonate566
 Calcium channel blocker393840
 ACEI/ARB424143
  • Data are shown as mean±SD, median (interquartile range), or percentage. BMI, body mass index; GI, gastrointestinal; PTH, parathyroid hormone; ESA, erythropoiesis-stimulating agent; IV, intravenous; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

  • a All values were obtained at the time of first prescription of calcium-based phosphate binders in the Dialysis Outcomes and Practice Patterns Study.

  • b All values were obtained at the time point of prognostic score calculation for matching (i.e., preceding the starting point for survival analysis).

  • c N control patients per stratum ranged from 1 to 91 for a total of 9594 distinct patients; note that patients could contribute to more than one stratum. Each stratum was assigned equal weight for calculating means.

  • d Includes calcitriol, doxercalciferol, paricalcitol, maxacalcitol, alphacalcidol, and falecalcitriol.

  • e Because the study population was restricted to those who had been prescribed calcium-based phosphate binders, all patients not prescribed calcium carbonate were prescribed calcium acetate.